预约演示
更新于：2026-06-17
Betamethasone Sodium Phosphate
磷酸钠倍他米松
更新于：2026-06-17
概要
基本信息
原研机构 |
非在研机构 |
权益机构- |
最高研发阶段批准上市 |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C22H30FNa2O8P |
InChIKeyODEOTKLZVXBMJD-LWCNAHDDSA-N |
CAS号151-73-5 |
关联
38
项与 磷酸钠倍他米松 相关的临床试验ChiCTR2600123920
Clinical study on the efficacy and safety of local application of bupivacaine liposome injection (PBL) combined with compound betamethasone injection (CBI) in reducing perioperative pain in patients undergoing total knee arthroplasty (TKA)
NCT07078786
Comparison of Effect of Antenatal Dexamethasone Versus Betamethasone on Antepartum Cardiactocography
ChiCTR2500096518
Randomized controlled study of improving preterm birth outcomes by reducing prenatal corticosteroid exposure
100 项与 磷酸钠倍他米松 相关的临床结果
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的转化医学
登录后查看更多信息
100 项与 磷酸钠倍他米松 相关的专利（医药）
登录后查看更多信息
1,051
项与 磷酸钠倍他米松 相关的文献（医药）2026-08-01JOURNAL OF CHROMATOGRAPHY A
Simultaneous determination of acylcarnitines, fatty acids, and amino acids by 3-nitrophenylhydrazine derivatization and ultra-high performance liquid chromatography/tandem mass spectrometry
Article
作者: Spégel, Peter ; Dannarm, Srinivas Reddy ; Ardalani, Hamidreza
Acylcarnitines (ACs) play a pivotal role in metabolism, most notably by facilitating the transport of fatty acids (FAs) into mitochondria for β-oxidation, a key step in cellular energy production. Dysregulation of AC, FA, and amino acid (AA) levels has been linked to various metabolic disorders, including cardiovascular diseases, neurodegenerative conditions, and cancer. Consequently, monitoring these metabolites in blood samples provides valuable insights into metabolic health and disease progression. In this study, we developed a method for the quantification of carnitine, seven ACs, fifteen FAs, and thirteen AAs in human serum using reversed-phase ultra-high performance liquid chromatography coupled with tandem mass spectrometry (UHPLC-MS/MS). By employing 3-nitrophenylhydrazine (3-NPH) derivatization, we achieved high detectability for ACs, with limits of detection (LODs) ranging from 0.01-0.27 ng/mL for ACs, 0.22-1.76 ng/mL for FAs and 0.17-18.25 ng/mL for AAs. Recovery rates ranged from 92-126% for ACs, 56-116% for FAs and 86-115% for AAs. Inter- and intra-day precision were below 20% for all metabolites except two FAs. This method provides a reliable and sensitive tool for the simultaneous analysis of ACs, FAs, and AAs in serum, with potential applications in clinical diagnostics and metabolic research.
2026-07-01Journal of neonatal-perinatal medicine
Extreme preterm infants of birth weight <750 g and gestational age <26 weeks, survival trends and morbidity predictors over nearly two decades, single centre experience
Article
作者: Mustafa, Ahmad ; Khan, Muhammad Anwar ; Hassosah, Mohammad ; Faden, Yaser ; Alallah, Jubara ; Sahafi, Ashraf ; Hanafi, Ehab ; Ahmed, Abrar ; Alhindi, Mohammed ; Al Qurashi, Mansour ; Al Marzouki, Hashem ; AlNajjar, Hend
Introduction:
Extreme preterm infants (EPI), born at <26 weeks’ gestation and weighing <750 g, represent the most vulnerable subset of preterm neonates with the highest risk of mortality and major morbidities. Despite significant advances in neonatal/perinatal care, outcomes for this population remain a major clinical challenge.
Objective:
To evaluate temporal trends in survival, morbidity profiles, and predictors of in-hospital survival among inborn extreme preterm infants of birth weight <750 g and gestational age < 26 weeks over an 18-year period in a tertiary-level neonatal intensive care unit (NICU).
Methods:
This retrospective cohort study included 134 inborn EP infants admitted between 2002 and 2019. The primary outcome was survival to hospital discharge; secondary outcomes included rates of several prematurity-related morbidities. Multivariable logistic regression was used to identify independent predictors of survival.
Results:
Survival to discharge increased over time from 29% (2002–2007) to 61% (2014–2019) (
p
= 0.009). Antenatal corticosteroid (ACS) (a OR 2.9, 95% CI 1.05–8.04,
p
= 0.049) and cesarean delivery (aOR 2.88, 95% CI 1.03–8.07,
p
= 0.044) were independently associated with increased odds of survival. Early hypotension (aOR 0.28, 95% CI 0.12–0.67,
p
= 0.004) and severe IVH (aOR 0.39, 95% CI 0.16–0.94,
p
= 0.035) were significantly associated with increased mortality. The incidence of severe IVH declined from 46% to 26% over the study period, while rates of PVL and surgical NEC showed downward trends. BPD (51%) and severe ROP (19%) remained relatively unchanged.
Conclusions:
Over nearly two decades, survival among extreme preterm infants of birth weight <750 g ang gestational age <26 weeks improved significantly. ACS administration and cesarean birth were associated with an increased rate of survival. Early hypotension and severe IVH were predictors of mortality. Severe IVH, PVL, and surgical NEC declined during the last period. Ongoing advances in perinatal care and targeted neonatal interventions are essential to further improve outcomes in this high-risk population.
2026-07-01BIOMEDICAL CHROMATOGRAPHY
Article
作者: Guo, Yuanyuan ; Li, Chengwei ; Xu, Yingjie ; Xiao, Xiaohe ; Zhan, Xiaoyan ; Lu, Zongliang ; Wen, Jincai ; Zhang, Lele ; Huang, Siqi ; Bai, Zhaofang ; Chen, Xiaoyan ; Wang, Xianling
ABSTRACT:
Sophora tonkinensis
, a traditional Chinese medicine with heat‐clearing, detoxifying, and throat‐soothing properties, has shown potential in treating hepatitis, inhibiting tumors, and regulating immunity, but its active constituents and mechanisms remain unclear. We established a hepatocellular carcinoma (HCC) model in SD rats using diethylnitrosamine (DEN), with oral gavage of
S. tonkinensis
extract (STE) from Weeks 1 to 16, alongside model and normal control groups. Results showed that STE significantly reduced HCC incidence, reversed weight loss, decreased the number and volume of liver nodules, improved histopathological damage, and lowered serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP), and albumin (ALB) levels. Integrated transcriptomic (RNA‐seq) and metabolomic (LC–MS/MS) analyses revealed enrichment in arachidonic acid and glycerophospholipid metabolism. Quantitative real‐time polymerase chain reaction (qPCR) validation confirmed that STE restored hepatic lipid homeostasis and alleviated inflammation by activating the peroxisome proliferator‐activated receptor (PPAR) pathway and suppressing the IL‐17/TGF‐β axis. These findings clarify the core mechanisms of STE in preventing and treating HCC, providing a theoretical basis for its precise clinical application.
100 项与 磷酸钠倍他米松 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 溃疡性结肠炎 | 日本 | 1992-03-13 | |
| 克罗恩病 | 日本 | 1992-03-13 | |
| 睑缘炎 | 日本 | 1985-11-20 | |
| 结膜炎 | 日本 | 1985-11-20 | |
| 角膜炎 | 日本 | 1985-11-20 | |
| 耳炎 | 日本 | 1985-11-20 | |
| 炎症 | 美国 | 1974-12-31 | |
| 胶原蛋白疾病 | 日本 | 1973-01-31 | |
| 内分泌系统疾病 | 日本 | 1973-01-31 | |
| 心脏衰竭 | 日本 | 1973-01-31 | |
| 肾病综合征 | 日本 | 1973-01-31 | |
| 类风湿关节炎 | 日本 | 1973-01-31 | |
| 眼部炎症 | 日本 | 1964-10-07 | |
| 外耳炎 | 日本 | 1964-10-07 | |
| 中耳炎 | 日本 | 1964-10-07 | |
| 过敏性鼻炎 | 日本 | 1964-10-07 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床2期 | 139 | (SURF-200 (0.02% Betamethasone Sodium Phosphate in Vehicle)) | 窪積夢襯壓積憲醖窪觸 = 襯壓構淵鑰齋壓鏇繭廠 簾鑰艱製製窪餘醖憲醖 (簾網積憲齋蓋觸齋構鬱, 鹽淵顧憲鹽餘鬱齋構憲 ~ 獵網鏇網觸憲壓製鹹觸) 更多 | - | 2025-06-04 | ||
(SURF-200 (0.04% Betamethasone Sodium Phosphate in Vehicle)) | 窪積夢襯壓積憲醖窪觸 = 範憲襯鏇鹽夢構鬱觸憲 簾鑰艱製製窪餘醖憲醖 (簾網積憲齋蓋觸齋構鬱, 廠餘醖蓋窪鹹網鹹鹹憲 ~ 壓鏇製餘鹹齋觸衊繭顧) 更多 | ||||||
临床2期 | 1 | (Bupivacaine Hydrochloride and Betamethasone Sodium Phosphate) | 製遞築鬱鹹襯蓋壓觸襯(獵鏇艱廠夢糧鬱餘築淵) = 簾構鹽顧膚簾艱獵夢醖 蓋壓獵顧顧壓獵衊齋顧 (淵襯鑰鹹鏇鬱淵齋膚廠, 餘選簾繭築簾繭憲衊鬱 ~ 鹽範遞齋夢積餘遞築鏇) 更多 | - | 2020-11-02 | ||
(Bupivacaine Hydrochloride) | 製遞築鬱鹹襯蓋壓觸襯(獵鏇艱廠夢糧鬱餘築淵) = 鑰蓋蓋鹹憲鬱繭鏇鏇製 蓋壓獵顧顧壓獵衊齋顧 (淵襯鑰鹹鏇鬱淵齋膚廠, 齋廠顧齋築築遞襯壓蓋 ~ 衊醖鹽齋糧艱衊醖鬱遞) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用